Showing results (1-10 of 15) with videos related to
Sort By:
Pageof 2
Cancer Biology & Therapy|August 13, 2002
Paclitaxel-induced FasL-independent apoptosis and slow (non-apoptotic) cell deathMikhail V Blagosklonny, Robert Robey, M Saeed Sheikh, et al.Journal of Chemical Information and Modeling|April 22, 2022
Performance Analysis of CP2K Code for Ab Initio Molecular Dynamics on CPUs and GPUsDewi Yokelson, Nikolay V Tkachenko, Robert Robey, et al.Molecular Cancer Research : MCR|March 2, 2011
Upregulation of ABCG2 by romidepsin via the aryl hydrocarbon receptor pathwayKenneth K W To, Robert Robey, Zhirong Zhan, et al.Cell Cycle (Georgetown, Tex.)|April 16, 2003
Low and high concentrations of the topo II inhibitor daunorubicin in NIH3T3 cells: reversible G2/M versus irreversible G1 and S arrestWilfred D Stein, Robert Robey, Carol Cardarelli, et al.Novartis Foundation Symposium|May 7, 2002
Reversal of multidrug resistance: lessons from clinical oncologySusan F Bates, Clara Chen, Robert Robey, et al.Cell Cycle (Georgetown, Tex.)|February 16, 2012
Retained platinum uptake and indifference to p53 status make novel transplatinum agents active in platinum-resistant cells compared to cisplatin and oxaliplatinRobert F Murphy, Edina Komlodi-Pasztor, Robert Robey, et al.Oncogene|January 16, 2002
Differential sensitivity of cancer cells to inhibitors of the epidermal growth factor receptor familyPhilippe C Bishop, Timothy Myers, Robert Robey, et al.Cancer Research|November 5, 2002
MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumorsJerry Jaboin, Jason Wild, Habib Hamidi, et al.Molecular Cancer Therapeutics|December 17, 2002
Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicityMikhail V Blagosklonny, Robert Robey, Dan L Sackett, et al.Molecular Pharmaceutics|September 25, 2010
Survivin is not induced by novel taxanesNima Sharifi, Jun Qi, Susan Bane, et al.Pageof 2